Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma

Table 5

Association between clinicopathologic features associated with OS and first-line systemic therapy regimens. The variability of the number of metastatic sites is presented as the 75th percentile to better reflect the true variability rather than displaying the median.

Systemic therapy	Median age (years)	Female : male ratio	Median time to metastases (years)	Number of metastatic sites, 75th percentile
Gemcitabine + docetaxel	56.5	2.6	0.23	5
Gemcitabine	72	1.3	0.78	2
Doxorubicin-alkylator combo	56.2	1	0	2
Liposomal doxorubicin	66.7	2.9	1.0	3.5
Doxorubicin	58.7	5	0	5
Alkylator, single	65.4	2	0.81	3.5
Tyrosine kinase inhibitors	51.7	1.3	1.1	3.5
Other combos	58.7	1.6	0.56	2
Other single agents	51.8	2.3	1.1	3
None	55.2	1.6	1.5	2
value	0.20	0.66	0.04	0.10

Defined as number at which 75% had fewer and 25% had greater metastases.